Research
Hormonal
Semaglutide and tirzepatide are effective medication options for obesity management.
Practitioners can consider semaglutide and tirzepatide as viable options for treating obesity.
StrongSupportsmedium confidence
Based on the data reviewed, both semaglutide and tirzepatide are effective medication options for obesity management.
Why this rating
The claim is based on a review of data, indicating a strong level of evidence.
Source
Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity
Timothy Nguyen et al. · American Journal of Therapeutics · 2023
DOI 10.1097/mjt.0000000000001643
reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide is $1845 and $985, respectively.Strong
- If 1%, 5%, or 10% of the population aged 60 years or older is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →